Olga Gubaryeva: Difference between revisions
Expand source-linked author records; preserve work-specific attribution |
Add complete multilingual reference and language navigation |
||
| Line 1: | Line 1: | ||
<div class="wiki-language-nav" style="padding:0.75em; border:1px solid #b5c8cd; border-radius:0.5em; margin-bottom:1em;">[[Olga Gubaryeva|English]] · [[Olga Gubaryeva/uk|Українська]] · [[Olga Gubaryeva/es|Español]] · [[Olga Gubaryeva/fr|Français]] · [[Olga Gubaryeva/de|Deutsch]] · [[Olga Gubaryeva/pt|Português]]</div> | |||
'''Olga Gubaryeva''' is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography. | '''Olga Gubaryeva''' is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography. | ||
Latest revision as of 00:52, 12 November 2026
Olga Gubaryeva is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography.
Documented work
Coauthor of a 26 July 2025 editorial concerning vaccine-circulation governance.
Research context: Pharmaceutical administration, corporate responsibility and anti-corruption proposals.
Named collaborators on this work: Valerii Shapovalov, Oleksandr Veits and Olena Lavoshnyk.
Inclusion records authorship of the cited work, not endorsement of every later Vision 2035 proposal. Publication affiliations are historical unless separately updated.
See People and attribution and Research network.